Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment

Recruiting

• Conditions: Thyroid Cancer

• Registration Number: NCT03624751
• Lead Sponsor: Taichung Veterans General Hospital

Brief Summary

The prevalence of thyroid cancer has increased in recent decades. Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan. This is a prospective, observational study, aiming to observe the difference of metabolic profiles between patients choose Thyrogen® injection and Eltroxin® withdrawal.

Detailed Description

1. Objective： To observe the difference between Thyogen® injection or Eltroxin® withdrawal on metabolic profile.

2. Background and method:： The prevalence of thyroid cancer has increased in recent decades. Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan. This is a prospective, observational study, aiming to observe the difference of metabolic profiles between patients choose Thyrogen® injection and Eltroxin® withdrawal.

Inclusion ： Patient number: 500人

Inclusion criteria :

1. Patients with diagnosis of thyroid cancer。

2. Patients who need radioiodine therapy or scan。

Exclusion criteria:

1. Patients cannot cooperate with blood test.。

2. Patients cannot cooperate with radioiodine therapy。 Study design： Prospective, observational study。

Method： We will collect 20cc blood and 20 cc urine before and after radioiodine therapy during each visit (total 3 visits) and check lipid profiles, glucose profiles and inflammation markers. We will compare the difference between results of patients undergoing Thyrogen® injection and Eltroxin® withdrawal.

Study Timeline

• Study First Submitted: 2018-05-24
• Study Start: 2018-06-30
• Status Verified: 2018-08
• Study First Submitted QC: 2018-08-08
• Last Update Submitted: 2018-08-08
• Study First Posted: 2018-08-10
• Last Update Posted: 2018-08-10
• Primary Completion: 2028-06-30
• Study Completion: 2030-06-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

1. Patients with diagnosis of thyroid cancer。
2. Patients who need radioiodine therapy or scan。

Exclusion Criteria

1. Patients cannot cooperate with blood test.。
2. Patients cannot cooperate with radioiodine therapy。

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Zung's Self-reported depression scale	1 month	Depression symtpoms

Secondary Outcome Measures

Name	Time	Method
Brain-derived neurotrophic factor	1 month	BDNF
VCAM-1	1 months	adhesion molecules
orexin	1 month	An associated factor for depression
Body composition	1 months	Fat component percentage to lean mass percentage ratio
CRP	1 months	inflammation marker
Metabolic syndrome	1 months	The number of conponents for metabolic syndrome

Trial Locations

Locations (1)

Division of Endocrinology and Metabolism in Taichung Veterans General Hospital; 🇨🇳 Taichung, Taiwan